Your browser doesn't support javascript.
loading
Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma.
Agrusa, Jennifer E; Kothari, Viral D; Brown, Austin L; Masand, Prakash M; Lewis, Gary D; Teh, Bin S; Paulino, Arnold C; Silva-Carmona, Manuel D; Melicoff, Ernestina; Allen, Carl E; Gramatges, Monica M.
Afiliação
  • Agrusa JE; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Kothari VD; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Brown AL; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Masand PM; Dan L. Duncan Comprehensive Cancer Center, Houston, TX, USA.
  • Lewis GD; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Teh BS; Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
  • Paulino AC; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.
  • Silva-Carmona MD; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.
  • Melicoff E; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Allen CE; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Gramatges MM; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Leuk Lymphoma ; 61(10): 2419-2427, 2020 10.
Article em En | MEDLINE | ID: mdl-32519904
ABSTRACT
Survivors of childhood Hodgkin lymphoma (HL) are at risk for pulmonary late effects, but whether survivors also experience pulmonary dysfunction early off therapy is not well understood. We determined the incidence of pulmonary dysfunction in children/adolescents with HL at entry into survivorship, as well as risk factors related to this outcome. Survivors in clinical remission and with a pulmonary function test (PFT) obtained 2-6 years off therapy were included. Seventy-five of 118 subjects met eligibility criteria (mean age at diagnosis 13 years, mean time off therapy 40 months). Survivors of HL had a higher than expected incidence of pulmonary dysfunction at entry into survivorship (40/75 [53%] had an abnormal DLCO and/or a restrictive or obstructive impairment). Evidence for diffusion impairment was associated with female sex (odds ratio [OR] = 3.19, p = .04). Longitudinal follow-up studies are needed to determine if early evidence of pulmonary dysfunction predicts risk for later onset pulmonary outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article